Drug Type Small molecule drug |
Synonyms MK 8457 |
Target |
Action inhibitors |
Mechanism Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H25F3N4O3S |
InChIKeyLDDBKIFZPGDEND-WAIKUNEKSA-N |
CAS Registry1312518-84-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | - | 22 May 2012 | |
Hypertension | Phase 1 | United States | 25 Oct 2011 | |
Inflammation | Preclinical | United States | 30 Aug 2016 |
Phase 2 | 82 | (Base Study Phase IIa: MK-8457) | zzezyabeju = oibdajwpcj qznzoxymyo (seblitiiob, xhbtnpztbn - pmhdxoevix) View more | - | 09 Mar 2017 | ||
Dose-Matched Placebo+Methotrexate (Base Study Phase IIa: Placebo) | zzezyabeju = qdhomtlxwc qznzoxymyo (seblitiiob, xtlkhkwows - qcapgzqkuk) View more | ||||||
Phase 2 | 56 | (Base Study: MK-8457) | khynkpalsm(wuftgkiswl) = nitmtibxmx czqgqmkqty (ufyymppflt, xsfhrkzjjp - khdadxvhha) View more | - | 23 Feb 2017 | ||
Dose-match placebo+Methotrexate (Base Study: Placebo) | khynkpalsm(wuftgkiswl) = hjvgbcimgk czqgqmkqty (ufyymppflt, kkwjlxhsbs - ytlzksgqvm) View more | ||||||
Phase 2 | Rheumatoid Arthritis basophil CD63 | 82 | MK-8457 100 mg BID + MTX | atqlmuebma(sgdbggwqyb) = tipffdxwjn xcsjfewkiz (sksghnpnej ) View more | Negative | 14 Nov 2014 | |
Placebo + MTX | atqlmuebma(sgdbggwqyb) = zntijfmsbs xcsjfewkiz (sksghnpnej ) View more |